The Relevance of Some Physiological Parameters in Evaluating the Safety of Two Vaccine Formulation Against Contagious Agalaxia in Goats

The safety assessment of the experimental vaccine formula Agalaxin forte containing a mineral adjuvant (aluminum hydroxide) as well as an organic adjuvant (anaculture of Staphylococcus aureus), was based on haematologic, biochemical, and clinical milk cell population tests performed on goats (n = 44), as a target species, following a specific protocol. The oscillations of the determined physiological indicators were characterized by a general position between the reference values and unimportant deviations, without any clinical, biological or pathological connotation. In evaluating the safety of the Agalaxin vaccine formula, the potential risks have been identified as related to experimental dose (double dose or three successive doses) and the post-vaccine adverse reactions which consisted of ephemeral local reaction (30.1%), of reduced intensity. Ultimately, the safety and innocuity were appreciated as being good, with a high level of safety for all experimental variables and doses of the investigated Agalaxin forte vaccine series.